Immunohistochemical expression of s100a11 (Calgizzarin) in skin diseases

Calgizzarin (S100A11) is an S100 protein family member with several functions. It is defined by EF-hand motifs that bind calcium and the ability to undergo conformational changes that regulate diverse cellular processes. It modulates enzyme activity, regulates cell growth via p21-mediated pathways, and participates in nuclear signaling. Dysregulation of S100A11 is implicated in multiple human diseases, including cancers (renal, prostate, breast, and hepatocellular carcinoma), metabolic disorders such as type 2 diabetes, neurological diseases including amyotrophic lateral sclerosis and autoimmune encephalitis, vascular calcification, and inflammatory conditions such as osteoarthritis. In dermatology, S100A11 contributes to epidermal differentiation, barrier function, and immune regulation. Its expression is context-dependent: downregulated in atopic dermatitis (AD), upregulated in chronic hand eczema, and involved in melanoma and other tumor microenvironments. Immunohistochemical studies reveal its localization in keratinocyte nuclei, cytoplasm, and plasma membrane, highlighting both intracellular and extracellular roles, including dimerization-mediated cell signaling. These properties position S100A11 as a role player in both dermatological and systemic illnesses, where it could serve as a therapeutic target and vital biomarker. Understanding S100A11-mediated pathways may inform disease diagnosis, prognosis, and the development of targeted interventions.